ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag anti inflammatory drugs culture

Pain Meds Fight Bacteria
Daniel Cossins | Mar 13, 2014 | 4 min read
Researchers show that some anti-inflammatory drugs may inhibit bacterial growth by blocking a protein component that is important in DNA replication.

 
Cas9 enzyme
Molecular Glue ‘Shreds’ Cas9 and Enables a New Form of CRISPR Control
Ida Emilie Steinmark, PhD | Apr 26, 2023 | 3 min read
In a bid to address safety concerns about immune reactions during treatment with CRISPR-based therapeutics, a new technique speeds up how quickly the body destroys the DNA-cutting enzyme Cas9.
Cellular Senescence: Why Do Cells Stop Dividing?
Cellular Senescence: Why Do Cells Stop Dividing?
Elina Kadriu | Feb 28, 2023 | 4 min read
Senescent cells undergo major morphological and metabolic changes when at the end of their lifespan. 
istock
AI Helps Predict Winners and Losers in Clinical Trials
Roni Dengler, PhD | Aug 3, 2021 | 4 min read
Pradipta Ghosh has plans to revolutionize the drug discovery pipeline.
A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Amos Zeeberg, Undark | Feb 27, 2023 | 8 min read
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
Chloroquine Protects Against Zika In Vitro
Marcia Triunfol | May 12, 2016 | 3 min read
The antimalarial drug reduces the number of infected Vero and human brain microvascular endothelial cells—among other cell types—in culture, researchers report in a preprint.
Tricky T Cells
Katherine Bagley | Jan 1, 2010 | 4 min read
By Katherine Bagley Tricky T Cells A new lymphocyte behind autoimmunity has created feverish excitement—and raised as many questions as it answers. TGF-β-Stimulated T cells; stained with a DNA-specific fluorochrome (blue), anti-RORγ (red) and anti-Foxp3 (green) monoclonal antibodies. Courtesy of Liang Zhou As the number of people suffering from autoimmune and inflammatory diseases continues to grow, scientists are
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Getting Drugs Past the Blood-Brain Barrier
Amanda B. Keener | Nov 1, 2017 | 10+ min read
To treat neurological disease, researchers develop techniques to bypass or trick the guardian of the central nervous system.

Run a Search

ADVERTISEMENT